Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations.

摘要: To explore the validity and prognostic significance of minimal residual disease detection by quantitative polymerase chain reaction (qPCR) in patients acute myeloid leukemia (AML) bearing Nucleophosmin (NPM1) mutations, we quantified mutants 194 bone marrow samples from 38 with a median follow-up time 20.6 months. Following induction chemotherapy, 2.78 log decline mutant copy number was observed. Relapse always accompanied significant increase numbers (P<0.001). After achieving complete remission (CR), significantly higher subsequent relapse than those remaining continuous CR Presence detectable after treatment predicted if no further chemotherapy administered. Furthermore, any rise signals during serial had 3.2-fold risk compared to persistently low or undetectable Patients who could achieve reduction <0.1% internal control longer overall survival (OS) (P=0.004) relapse-free (RFS) Failure 2 logs consolidation shorter OS (P=0.01) RFS (P=0.001). In conclusion, qPCR monitoring may have impact AML NPM1 mutations.